Bladder Cancer xx (20xx) x-xx Abstract. 9 Background: Bacillus Calmette-Guerin (BCG) is the recommended therapy for high and intermediate risk non-muscle invasive bladder cancer (NMIBC), but treatment failure is common. While a radical cystectomy is recommended after BCG failure, some patients desire bladder preservation and others are poor surgical candidates. Salvage chemotherapy treatments may be offered to this subgroup of patients. 10 11 12 13 Objective: To assess if combination, hyperthermic Gemcitabine and Docetaxel chemotherapy (GEM/DOCE) is a safe and effective salvage option for treating NMIBC.
The 60-patient cohort had a median age at treat-185 ment of 73 years ( courses, or number of positive prior bladder patholo-236 gies (Fig. 3) .
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Clinical predictors of recurrence 238 In order to identify clinical predictors of recur- 
